Next Generation Ultrasound: Evolution in Diagnosis
                   and Therapy




          Shri Shanmugham, Senior Re...
Focus Points


 Ultrasound Overview

 Advancements:
  •   Elastography
  •   CEUS
  •   HIFU


 Conclusion




           ...
Ultrasound Overview

 Ultrasound equipment is experiencing an innovative
 phase with advances that include 3D/4D imaging,
...
Ultrasound Advancements - Elastography

 Elastography exploits the smaller elasticity profile of
 malignant tissues to enh...
SuperSonic Imagine – Company Profile

 www.supersonicimagine.fr

                                                         ...
Ultrasound Advancements - HIFU

 High Intensity Focused Ultrasound (HIFU) is an
 emerging technology for the non-invasive ...
Theraclion – Company Profile

 www.theraclion.com

                                                             Applicatio...
Ultrasound Advancements - CEUS

 Contrast Enhanced Ultrasound (CEUS) is a
 technology where contrast agents such as gas fi...
Conclusion

 HIFU and CEUS is poised for the greatest growth potential in the next decade. It is premature to estimate the...
Major Vendors in the Ultrasound Segment




                                          10
Next Steps


 Request a strategic approach document for a Growth Partnership Service or
 Growth Consulting Service to supp...
Your Feedback is Important to Us


          What would you like to see from Frost & Sullivan?

Growth Forecasts?

Competi...
For Additional Information



Katja Feick                  Noel Anderson
Corporate Communications     European Vice Presid...
Upcoming SlideShare
Loading in …5
×

Next Generation Ultrasound in Europe: Evolution in Diagnosis and Therapy

3,397 views
3,189 views

Published on

Ultrasound equipment is experiencing an innovative
phase with advances that include 3D/4D imaging, Elastography, customized probe design, organ specific imaging, and specialized post-processing software. This presentation gives further details on the European market for Elastography, High Intensity Focused Ultrasound (HIFU) and Contrast Enhanced Ultrasound (CEUS)

Published in: Business
0 Comments
5 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,397
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
60
Comments
0
Likes
5
Embeds 0
No embeds

No notes for slide

Next Generation Ultrasound in Europe: Evolution in Diagnosis and Therapy

  1. 1. Next Generation Ultrasound: Evolution in Diagnosis and Therapy Shri Shanmugham, Senior Research Analyst Healthcare March 4, 2010
  2. 2. Focus Points Ultrasound Overview Advancements: • Elastography • CEUS • HIFU Conclusion 2
  3. 3. Ultrasound Overview Ultrasound equipment is experiencing an innovative phase with advances that include 3D/4D imaging, Elastography, customized probe design, organ specific imaging, and specialized post-processing software With safety standards being strictly enforced by regulatory bodies, ultrasound has also emerged to be the major tool for secondary diagnosis The potential for ultrasound is on the rise and they are also being employed in surgery, interventional procedure, renal, obstetrical, breast, pelvic, thyroid, scrotal, prostate, transrectal, and musculoskeletal applications. Developments in elastography, and dedicated probe design have attracted sales for ultrasound 3D and 4D (volumetric) imaging utility is poised for expansion for many ultrasound application, including therapeutic ultrasounds. Obstetrics and gynaecology employ the full application of ultrasound volumetric imaging in Europe. 3
  4. 4. Ultrasound Advancements - Elastography Elastography exploits the smaller elasticity profile of malignant tissues to enhance the imaging differences with benign tissues. Elastography is effective for estimation of lesion size. Consecutively, biopsy rates in benign lesions are reduced and proving to be more economical for patients. Elastography is gaining edge for better detection of thyroid cancer, particularly in nodules with undermined cytology, owing to extensive clinical research. Elastography for thyroid and liver will generate the next wave of interest with respect to ultrasound application. However, all equipment manufacturers are trying Elastography on thyroid and liver with varying success. Elastography is in a budding stage and will evolve to become a potential and versatile ultrasound application. Currently, Elastography is available with full potential for breast diagnosis from Siemens, Philips and SuperSonic Imagine. Source: SuperSonic Imagine 4
  5. 5. SuperSonic Imagine – Company Profile www.supersonicimagine.fr Image Total Number of Ultrasound Products: 1 Application Mode The company’s USP is its MultiWave ultrasound platform that leverages the innovations and speed in the videogame industry and supports both high quality B-Mode imaging General Tissue and ShearWave Elastography. ShearWave Elastography Imaging Yes Harmonic Yes enables real-time, quantitative and reproducible tissue elasticity imaging with a color coded elastrography map. M-Mode and Breast Yes 2D Yes ShearWave Elastography generates, captures and quantifies the speed of shear wave propagation and using the Young's Abdomen Yes Triplex No modulus derives the stiffness of tissue in kilopascals. Contrast The product – The Aixplorer ultrasound system is clinically Urology No Harmonic No dedicated with packages for the breast, abdomen and thyroid with other dedicated applications on the horizon for the future. OB/GYN No 3D/4D No In support of its first application, SuperSonic Imagine has Color undertaken a large, 2300 patient, worldwide breast clinical Surgery No Mapping Yes trail that will be published in the Spring of 2010. Therapeutic No Elastography Yes In August 2009, Aixplorer received the FDA approval and certification. 5
  6. 6. Ultrasound Advancements - HIFU High Intensity Focused Ultrasound (HIFU) is an emerging technology for the non-invasive treatment of certain tumors and other pathological conditions. It generates precise tissue necrosis and it hardly affects the neighboring tissue areas. HIFU is primarily utilized for the effective treatment for prostrate cancer. New HIFU developments are also taking place for the treatment of hyperparathyroidism. It has also been successful in the treatment of uterine fibroids. HIFU clinical trials are being conducted for treatment of kidney, pancreas, bladder and liver. HIFU treatment is not applicable for cancer treatment of brain, lungs, pelvic areas, lymph nodes or skin There are no effective standards governing the application of HIFU technology. Many standards have been proposed by researchers executing HIFU clinical trials. However, it is important to note that no single HIFU treatment procedure is regarded as an effective therapeutic option. Source: Theraclion 6
  7. 7. Theraclion – Company Profile www.theraclion.com Application Image Modes Total Number of Ultrasound Products: 1 Founded in 2004, Theraclion is a specialist for the non- invasive treatment of head and neck pathologies using General Imaging No Tissue Harmonic No High Intensity Focused Ultrasound (HIFU) The company is supported by internal scientific Breast No M-Mode and 2D No committees composed of surgeons and interventional radiologists. Abdomen No Triplex No The product Thyros is dedicated to the treatment of hyperparathyroidism (primary and secondary) Contrast Urology No Harmonic No A limited market launch of Thyros will occur in Q1 2010 in UK, Germany and Italy, followed by the rest of OB/GYN No 3D/4D No Europe. The product is CE marked and its FDA approval is Surgery No Color Mapping No pending. Therapeutic Yes Elastography No 7
  8. 8. Ultrasound Advancements - CEUS Contrast Enhanced Ultrasound (CEUS) is a technology where contrast agents such as gas filled micro bubbles are injected into the circulatory system with the objective of improving image quality. High echogenicity differences that exist between the gas filled micro bubbles and tissues enable a highly contrasted image CEUS is also expected to ascertain better diagnosis of prostate cancer. This is because the sensitivity of prostate cancer diagnosis increases significantly by performing targeted biopsy of the prostate with CEUS. The biggest growth area for CEUS is in the assessment of joint damage rheumatoid arthritis (RA) and osteo arthritis. With the advent of regenerative medicine, the objective is to track therapy response accurately. In the long-term future, contrast agents will become optimized for a desired set of harmonic characteristics. In other words, contrast agents will be specifically developed for a specific application (such as tissue perfusion for example). Source: GE Healthcare 8
  9. 9. Conclusion HIFU and CEUS is poised for the greatest growth potential in the next decade. It is premature to estimate the market size and growth rate for these two sectors at the moment because HIFU and CEUS are experiencing extensive clinical trials. The results of such trials yield varying success rates. However, it is imperative that more clinical trials would follow, given the government initiatives to promote non-radiological safety standards. HIFU requires extensive clinical validation by both controlled and uncontrolled methods. There is not an independent company in Europe for HIFU for clinical testing and HIFU product development. All HIFU companies have strategic partnerships with other HIFU companies and research clinics. Unlike diagnostic requirement, HIFU is eminently organ specific. Elastography will create a niche segment of opportunity within the ultrasound spectrum. The general ultrasound market is essentially saturated and revenues for vendors are generated by replacements. However, the technological edge that elastography offers for enhanced diagnosis, clients would be more compelled to invest in ultrasound equipment that has this feature. 9
  10. 10. Major Vendors in the Ultrasound Segment 10
  11. 11. Next Steps Request a strategic approach document for a Growth Partnership Service or Growth Consulting Service to support you and your team to accelerate the growth of your company. (enquiries@frost.com) +44 (0)20 7343 8383 Join us at our annual Growth, Innovation and Leadership 2010: A Frost & Sullivan Global Congress on Corporate Growth London, United Kingdom (www.gil-global.com) Register for the next Chairman’s Series on Growth: Growth Acceleration System: Leveraging the Growth Diagnostic Blueprint 17 March 2010 10:00 AM GMT (www.frost.com/growthEU) Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news) 11
  12. 12. Your Feedback is Important to Us What would you like to see from Frost & Sullivan? Growth Forecasts? Competitive Structure? Emerging Trends? Strategic Recommendations? Other? Please inform us by taking our survey. 12
  13. 13. For Additional Information Katja Feick Noel Anderson Corporate Communications European Vice President Healthcare New Business Development 0049 (0) 69 7703343 +44 (0)207 343 8389 katja.feick@frost.com noel.anderson@frost.com Siddharth Saha Director of Research Healthcare + 44 (0) 207 343 8374 siddharth.saha@frost.com 13

×